Letters sent to healthcare professionals in April 2017, including a reminder of the retigabine (Trobalt) withdrawal

A summary of letters sent to healthcare professionals, including an important reminder about the withdrawal of retigabine (Trobalt) from the market.

In September 2016 we told you about the withdrawal of retigabine (Trobalt) from the market.

In April 2017, a letter was sent reminding relevant healthcare professionals that all patients must be withdrawn from Trobalt by the end of June 2017.

Withdrawal of a patient should be gradual and take place over at least 3 weeks, in accordance with the prescribing information.

Letters were also sent about the following medicines in April 2017:

Article citation: Drug Safety Update volume 10 issue 10, May 2017: 3.

Published 24 May 2017